J&J Ottava FORTE Pivotal Resets the Soft Tissue Surgical Robotics Stack

Johnson & Johnson presented the FORTE pivotal trial results for its Ottava soft tissue surgical robot at the American Society for Metabolic and Bariatric Surgery annual meeting in San Antonio on May 5, with all primary safety and performance endpoints met across 30 Roux-en-Y gastric bypass patients at six U.S. sites and the 30-day follow-up window complete. The company filed for FDA De Novo classification on the basis of the FORTE pivotal package combined with the prior preclinical evidence, with the requested clearance covering general surgery indications including gastric bypass, sleeve-based procedures, small bowel resection, hiatal hernia repair, and upper abdominal surgery. The same week brought confirmation of Intuitive’s measured 2026 cardiac rollout following the January da Vinci 5 nine-indication clearance, the Boston Scientific-Penumbra shareholder vote scheduled for May 6 that moves the largest interventional acquisition of 2026 toward a second-half close, and Boston Scientific Q1 results that confirmed the strategic-acquirer balance sheets remain in active deployment mode for the platforms that fit the integrated commercial story. Read across the four, the soft tissue surgical robotics stack now has three credible cleared or near-cleared platforms, a measurably tighter pivotal trial design template than the field had been assuming, and a strategic-acquirer environment paying premiums for indication breadth and procedural workflow integration.

J&J Ottava FORTE Pivotal Hits Across the 30-Patient Roux-en-Y Cohort

Johnson & Johnson disclosed the Ottava FORTE pivotal results at ASMBS 2026 in San Antonio on May 5. The single-arm open-label prospective design enrolled 30 patients across six U.S. sites for Roux-en-Y gastric bypass and completed the 30-day post-procedure follow-up window, and the company reported that all primary safety and performance endpoints were met. The procedure cohort lost an average of roughly 13.6 kilograms in the first month, and Peter Schulam, J&J chief strategy officer for medtech, characterized the platform as integrating into existing hospital infrastructure in a way that could remove practical adoption barriers. J&J filed for FDA De Novo classification using the FORTE pivotal package combined with the prior preclinical evidence, with the requested indication coverage spanning gastric bypass, sleeve-based procedures, small bowel resection, hiatal hernia repair, and general upper abdominal surgery.

The FORTE design is the structural data point that surgical robotics founders should be reading carefully. A 30-patient single-arm pivotal at six U.S. sites with a 30-day primary follow-up is a meaningfully tighter regulatory enrollment than the field has historically assumed for soft tissue robotic systems, and the De Novo route combined with that enrollment signals that the FDA device center is willing to accept compact pivotal designs from sponsors that can deliver clean preclinical packages and well-controlled safety endpoints. The implication for founders building soft tissue robotic platforms is that the regulatory entry path has measurable design optionality, that the cost of the pivotal trial is a real lever rather than a fixed cost, and that the founders who run regulatory strategy alongside engineering from initial product architecture have a different cost-and-timeline conversation with the FDA than the founders who treat the pivotal as a single-design problem to be solved at the end of development.

Intuitive Cardiac Rollout Defines the Differentiation Lane Around Ottava

The FORTE result lands in an environment Intuitive Surgical has spent the first quarter of 2026 redesigning. The FDA cleared the da Vinci 5 system on January 26 for nine cardiac indications, including mitral valve repair, tricuspid valve repair, mitral valve replacement, and left atrial appendage closure. Intuitive announced a measured 2026 rollout to a limited number of U.S. sites, with a dedicated team building the clinical evidence, training programs, and cardiac-specific instruments and accessories that the new indication base requires. The company is also pursuing cardiac approvals in Europe, with the platform already cleared for cardiac use in South Korea.

The structural read is that the leader in soft tissue robotic surgery is moving the differentiation perimeter into a cardiac specialty where the procedural workflow is more complex, the training pipeline is longer, and the buyer environment values integrated platform credibility over the multipurpose surgical robotic positioning that defined the prior generation. Hugo and Ottava are positioned for general surgery and urology, and the cleared cardiac perimeter that Intuitive is now building does not directly intersect either platform’s first commercial cycle. The integrated commercial story that strategic acquirers are paying for, however, runs across all three platforms, and the founders building components that fit into general-surgery, urology, gynecology, or cardiac-robotic workflows have measurably different valuation conversations depending on which of the integrated stacks the component fits.

Boston Scientific Penumbra Shareholder Vote Closes the Largest 2026 Interventional Deal

The Penumbra shareholder vote on the $14.5 billion Boston Scientific acquisition is scheduled for May 6, with Boston Scientific guiding for a second-half 2026 close subject to the remaining regulatory clearances. The deal represents the largest interventional acquisition of 2026 to date and consolidates the venous thrombectomy and stroke-care interventional categories under a single platform alongside the prior Boston Scientific Q1 portfolio additions, including the closed Nalu Medical transaction with $588 million preliminary consideration, the completed Cortex acquisition, and the signed Scivita Medical agreement. Boston Scientific reported Q1 net sales of $5.203 billion, an 11.6% year-over-year increase with 9.4% organic growth, and electrophysiology and interventional cardiology and vascular therapies were the named demand drivers across the cardiovascular segment.

The Penumbra close confirms that the strategic-acquirer balance sheets remain in active deployment mode for platforms that fit the integrated commercial story. Interventional founders building platforms in venous, peripheral arterial, neurovascular, and structural heart adjacencies should be reading the Boston Scientific deployment cadence as evidence that the buyer environment is paying premiums for the platforms that can demonstrate clean integration into the cardiovascular and neurovascular procedural workflows. The same pattern shows up at Zimmer Biomet, which delivered Q1 2026 organic constant-currency growth of 2.9%, raised the full-year EPS guidance to $8.40 to $8.55 from the prior $8.30 to $8.45, and increased the free cash flow growth guidance to 9% to 11% from the prior 8% to 10%. The sustained operating performance at the strategic-acquirer scale is the demand environment for the next round of medtech transaction activity.

What the FORTE Design Changes for Surgical Robotics Founders

Three operational shifts follow from the FORTE pivotal data and the broader week. The first is that the soft tissue surgical robotics regulatory pathway has measurable design optionality, and the founders running regulatory strategy from initial product architecture have a different cost-and-timeline conversation with the FDA than the founders who treat the pivotal as a fixed-design problem at the end of development. The second is that the integrated commercial story strategic acquirers are pricing across general surgery, cardiac, and interventional platforms is now the unit of valuation, and the components that fit cleanly into one of the integrated stacks have a different conversation with the buyer environment than standalone point solutions. The third is that the strategic-acquirer balance sheets remain in active deployment mode at the largest scale of the medtech ecosystem, and the founders whose platforms arrive at the strategic conversation in the second half of 2026 with credible commercial momentum will see the active deployment environment that the Boston Scientific Penumbra close confirms.